Advertisement

Topics

Alder BioPharmaceuticals® Announces Second Quarter 2017 Financial and Operating Results

11:05 EDT 8 Aug 2017 | BioMedReports - Blog

– Positive top-line PROMISE 1 study results further support eptinezumab’s unique clinical profile –

– $161.5 million from recent public offering expected to enable continued advancement of eptinezumab through pivotal studies, a planned Biologics License Application and achievement of other key activities –

– Conference call set for 5 p.m. EDT today –

BOTHELL, Wash., Aug. 08, 2017 (GLOBE NEWSWIRE)

Read more...

Original Article: Alder BioPharmaceuticals® Announces Second Quarter 2017 Financial and Operating Results

NEXT ARTICLE

More From BioPortfolio on "Alder BioPharmaceuticals® Announces Second Quarter 2017 Financial and Operating Results"

Quick Search
Advertisement
 

Relevant Topics

Biotherapeutics
The field encompassing therapeutic materials produced using biological means, including recombinant DNA technology. Biotherapeutics, also known as biotech drugs or biologics, are therapies derived from living organisms. By harnessing these living cells...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...